Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01951274 · ClinicalTrials.gov registry record · Phase 2
VPD-737 for Treatment of Chronic Pruritus
A Phase 2 study, sponsored by Vyne Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 257
- Enrollment target
NCT01951274: Completed Phase 2 study, sponsored by Vyne Therapeutics.
NCT01951274 is a Phase 2 study that has completed, run by Vyne Therapeutics. The registered enrollment target is 257 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01951274, a Phase 2 study, has completed, sponsored by Vyne Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 257 participants
- Enrollment target
Study Summary
A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments
Interventions
- DRUG Placebo
- DRUG VPD-737
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2013-10-15 |
| Est. Completion | 2014-12-02 |
| Phase | Phase 2 |
What the finished NCT01951274 record still lists
NCT01951274 is an interventional study that assigns participants to a tested intervention. The registered 257 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01951274 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01951274 about?
NCT01951274 is a clinical study titled "VPD-737 for Treatment of Chronic Pruritus". A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments
What is the current status of trial NCT01951274?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 257 participants. The study started on 2013-10-15. Estimated completion is 2014-12-02.
What interventions are being tested in trial NCT01951274?
The interventions under investigation include: Placebo (DRUG), VPD-737 (DRUG).
Who is sponsoring clinical trial NCT01951274?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01951274's enrollment target sits among peer trials
257 214th of 2000 higher than 1,786 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03618550 · 257 participants · Phase 2
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- NCT04674267 · 257 participants · NA
Resilience and Equity in Aging, Cancer, and Health (REACH)
- NCT06099288 · 257 participants · NA
Strong Families Start at Home/Familias Fuertes Comienzan en Casa
- NCT06207084 · 257 participants · NA
The Fit With Us Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI